Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 1, 2006, Pages 62-67

  Hammel, Jeffrey P ^a,f   Bhavnani, Sujata M ^a,b,e   Jones, Ronald N ^c,d   Forrest, Alan ^b   Ambrose, Paul G ^a,b,e  

^a Albany Medical College   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c JMI LABORATORIES   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ORDWAY RESEARCH INSTITUTE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

AGE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTER; HOSPITAL BED CAPACITY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SIMULATION;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; COMPUTER SIMULATION; DRUG RESISTANCE, BACTERIAL; ENTEROBACTER; HUMANS; LINEAR MODELS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MODELS, GENETIC; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RESEARCH DESIGN;

EID: 29944438867     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.1.62-67.2006     Document Type: Article

References (10)

1. Ballow, C. H., and J. J. Schentag. 1992. Trends in antibiotic utilization and bacterial resistance. Diagn. Microbiol. Infect. Dis. 15(2 Suppl.):37S-42S.
2. Bhavnani, S. M., W. A. Callen, A. Forrest, K. K. Gilliland, D. A. Collins, J. A. Paladino, and J. J. Schentag. 2003. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. Am. J. Health-Syst. Pharm. 60:1962-1970.
3. Bhavnani, S. M., J. P. Hammel, A. Forrest, R. N. Jones, and P. G. Ambrose. 2003. Relationships between patient- and institution-specific variables and decreased susceptibility of gram-negative pathogens. Clin. Infect. Dis. 37:344-350.
4. Fridkin, S. K., R. Lawton, J. R. Edwards, F. C. Tenover, J. E. McGowan, and R. P. Gaynes. 2002. Intensive Care Antimicrobial Resistance Epidemiology Project. National Nosocomial Infections Surveillance Systems hospitals. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg. Infect. Dis. 8:702-707.
5. Fritsche, T. R., H. S. Sader, and R. N. Jones. 2003. Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY Antimicrobial Surveillance Program (North America: 2001-2002). Diagn. Microbiol. Infect. Dis. 47:435-440.
6. Lesch, C. A., G. S. Itokazu, L. H. Danziger, and R. A. Weinstein. 2001. Multi-hospital analysis of antimicrobial usage and resistance trends. Diagn. Microbiol. Infect. Dis. 41:149-154.
7. Klein, J. P., and M. L. Moeschberger. 1997. Survival analysis: techniques for censored and truncated data, p. 65-70. Springer-Verlag, New York, N.Y.
8. Rhomberg, P. R., R. N. Jones, and the MYSTIC Program (USA) Study Group. 2003. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn. Microbiol. Infect. Dis. 47:365-372.
9. Sader, H. S., D. J. Biedenbach, and R. N. Jones. 2003. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001). Diagn. Microbiol. Infect. Dis. 47:361-364.
10. Thornsberry, C., D. F. Sahm, L. J. Kelly, I. A. Critchley, M. E. Jones, A. T. Evangelista, and J. A. Karlowsky. 2002. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin. Infect. Dis. 34:S4-S16.